A transcriptional signature of resting mast cells is associated with improved disease outcome in HR+HER2- breast cancer.

A. Kirchmair C. Galassi E. García-Torralba Z. Trajanoski A. Buqué Lorenzo Galluzzi

Jul 2026 · Genes and Immunity · 0 citations · 71 references

Medicine

TL;DR

Analysis of transcriptional signatures of immune cell infiltration across three public transcriptomic datasets from patients with breast cancer suggests interactions between mast cells and non-malignant components of the breast cancer microenvironment, particularly fibroblasts, may shape disease progression and treatment sensitivity.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Sep 2026

Basal-like Phenotype Identifies Immunotherapy-Responsive Subset of HR+/HER2- Breast Cancer with Aggressive Clinical Behavior

Simple Summary HR+/HER2- breast cancer represents 70% of all breast cancers but has shown limited benefit from immunotherapy, with pathological complete response (pCR) rates of only 24–30% compared to 58–66% in triple-negative breast cancer (TNBC). This resistance has been considered an immutable biological characteris...

Fang-Yu He, Yu Wu, Lu Pan et al. · Cancers · 0 citations

Review Aug 2026

Advances in Targeting Immune Checkpoint Inhibitors and New Vaccination Strategies for Triple-negative Breast Cancers: An Update.

INTRODUCTION Triple-negative breast cancers (TNBCs) are a type of breast cancer (BC) characterized by the absence of ER, PR, and HER2 expression. They account for 10-15% of invasive BC cases and are known for being aggressive and highly metastatic. TNBC patients face limited effective treatment options due to the inher...

Parth Malik, V. Patel, R. Maitra et al. · Current Drug Targets · 0 citations

Review Sep 2026

Association of immune and proliferation gene signatures and stromal tumor-infiltrating lymphocytes with clinical outcomes in patients with stage I triple-negative breast cancer.

BACKGROUND One-third of patients with triple-negative breast cancer (TNBC) are diagnosed with stage I tumors. Biomarkers to stratify prognosis in this setting remain a major unmet need. METHODS Tissue samples and clinicopathologic data were retrieved from consecutive patients with stage I TNBC (defined as ER <10% and...

P. Tarantino, Tian-Yu Li, Laia Paré Brunet et al. · European Journal of Cancer · 0 citations

Open access Aug 2026

Single-cell analyses reveal a simple multi-gene transcriptomic signature with predictive power in prognosis and therapy effectiveness in triple-negative breast cancer

Re-analysis of single-cell RNA-sequencing data characterizes the diverse cell subtypes within the tumor and microenvironment of TNBC, supporting a luminal progenitor origin for the cancer and providing clues as to the factors involved in progression of the disease.

G. Davidson, V. Debien, Tom Sexton · bioRxiv · 0 citations

Review Open access Aug 2026

Decoding the tumor microenvironment of triple-negative breast cancer: from immune evasion to precision immunotherapy

A review summarizes the dynamic landscape of the TNBC immune microenvironment, focusing on the functional roles of tumor-infiltrating lymphocytes, tumor-associated macrophages, tumor-associated neutrophils, natural killer cells, and myeloid-derived suppressor cells in regulating antitumor immunity and therapeutic resis...

Hong-Yu Cao, Mei Tao, Xue-Yi Qin et al. · Frontiers in Immunology · 0 citations

Open access Sep 2026

Neutrophil-related gene signature predicts prognosis and immune microenvironment patterns in thyroid cancer.

BACKGROUND Thyroid carcinoma (THCA) represents the most prevalent malignancy of the endocrine system. Although the majority of patients exhibit favorable clinical outcomes, a subset still faces significant clinical challenges, including distant metastasis, recurrence, and poor response to therapeutic interventions, all...

Liang Chen, Chao-Hon Fu, Yang Chen et al. · Advances in Clinical and Exp... · 0 citations